Lysins are bacteriophage derived proteins that have antibacterial properties and play important physiological roles during the phage life cycle. These proteins are enzymatic by nature and have either muralytic, proteolytic or hydrolytic activity enabling them to lyse the cell wall of the target bacterium.
GangaGen has used its proprietary PATP to design novel lysin molecules to target both Gram positive and Gram negative pathogens. The most advanced of these is P128 (Staphtame), an Ectolysin that is active on Staphylococci and progressed to clinical trials in humans.